A Study of HS-10529 in KRAS G12D Patients With Advanced Solid Tumors
HS-10529 is an oral, highly selective, small molecular inhibitor of KRAS G12D. This study will evaluate the safety, tolerability, pharmacokinetics and clinical activity of HS-10529 in KRAS G12D patients with advanced solid tumors.
Advanced Solid Tumors
DRUG: HS-10529
The maximum tolerated dose (MTD) or maximum applicable dose (MAD), up to 24 months
Incidence and severity of treatment-emergent adverse events, up to 24 months|Plasma concentration of HS-10529, up to 36 months
This is a phase 1, first-in-human, study of HS-10529, consisting of dose escalation and dose expansion, which is aimed to assess the safety and tolerability of HS-10529 in KRAS G12D patients with advanced solid tumors and evaluate the preliminary efficacy of HS-10529.